Evidence map›Paper›PMID 34511843›Full record

ArticleMacromolecular symposia2021

Nanotechnology-Based Approach to Combat Pandemic COVID 19: A Review.

Brijesh Kumar Shukla, Himanshi Tyagi, Hema Bhandari, Seema Garg

Abstract read
In one paragraph

Article in Macromolecular symposia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brijesh Kumar ShuklaDepartment of Chemistry Amity Institute of Applied Sciences Amity University Sector-125 Noida Uttar Pradesh 201313 India.
Himanshi TyagiDepartment of Chemistry Amity Institute of Applied Sciences Amity University Sector-125 Noida Uttar Pradesh 201313 India.
Hema BhandariDepartment of Chemistry Maitreyi College University of Delhi Delhi 110021 India.
Seema GargDepartment of Chemistry Amity Institute of Applied Sciences Amity University Sector-125 Noida Uttar Pradesh 201313 India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of a novel Corona virus (COVID 19) originated on December 19 from China. The city of Wuhan, the capital city of Hubei province, China, is responsible for an outbreak of respiratory illness known as COVID 19 and it has been rapidly spread across the world claiming millions of lives. The sudden outbreak of novel Coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV), is a big concern for their speedy mitigation using the predictable treatment and creating its approach around the world. Researchers and doctors are in search of rapid diagnosis kit, drugs, and viral-resistant personal protective equipment (PPE) to clinical diagnosis, medication, and prevent the spread of COVID 19. A rational approach with adaptability and broad viewpoint to challenge the growing pain could be overcome by the application of appropriate technology. The nanotechnology-based approach can significantly serve the purpose of the current pandemic situation of COVID 19. But same time implementation of innovative and creative nanotech approach, there is a decisive need for the full knowledge of SARS-CoV-2 pathogenesis. Moreover, to defeat COVID 19, particularly nanotech-based system with their viral inhibitory properties to increase the effective nanotech approach is essential. In this scenario, this review aims to summarize the past, present, and future of nanotech-based systems that can be used to treat COVID 19, highlighting Nano-based compounds. Lastly, the potential application of the different category of Inorganic Nanomaterials/Inorganic organic conjugate /hybrid system and their practical applicability as suitable means for inspiring against COVID 19 has also been discussed.

Indexed as

2019‐nCoVantiviral agentscoronavirusCOVID 19nanoparticlesnanotechnologySARS‐CoVtherapeutics and diagnosis

Identifiers

PMID34511843
PMCPMC8420461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.